熱門資訊> 正文
在FDA专员Makary辞职后，Replimune激增
2026-05-14 01:07
- Replimune (REPL), which has been critical of the FDA over its application for a melanoma treatment, is up ~30% Wednesday, the day after FDA Commissioner Marty Makary tendered his resignation.
- Makary left his position Tuesday amid reported pressure from President Trump who noted that he had been having "some difficulty" heading the agency. Many in the pharmaceutical and biotech industries were also unhappy with his leadership.
- Replimune is the latest biopharma to have a spat with the agency. In April, the FDA rejected its melanoma therapy, RP1, plummeting shares, even though the company included input in its application from a Type A meeting.
- Makary responded to the attack with an op-ed defending the agency's decision in The Wall Street Journal. However, the newspaper's editorial board also published an editorial lamenting some of Makary's actions.
- In a just-published piece, Seeking Alpha investing group Galzus Research is maintaining a cautious buy rating and sees a potential for an RP1 resubmission with Makary gone.
More on Replimune Group
- Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1
- Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
- Replimune: Multiple Shots On Goal But A High Risk Binary Approaches
- FDA head Makary defends drug application rejections amid criticism
- RFK Jr. says no hand in rejecting Replimune’s lead asset
推薦文章
美股機會日報 | 戴爾盤前狂飆34%！大幅上調全年業績指引；字節擬採購數百萬顆高通AI ASIC芯片；太空概念突發利空，盤前集體回落
打新攻略 | 中籤即賺1.7萬港元？深演智能三日暴漲逾700%！天辰生物等火熱招股中，下一隻爆款新股是誰？
華盛早報 | 美伊據悉再延長休戰60天！Anthropic H輪估值9650億美元反超OpenAI；戴爾AI收入暴增，績后飆升近40%
5月29日外盤頭條：Anthropic新一輪融資后估值達9650億美元 機構料美伊達成協議概率較高
美股機會日報 | 4月PCE數據將出爐！通脹或創近三年新高；特朗普擬入股無人機公司，UMAC盤前狂飆30%；軟件股盤前集體反攻
一圖看懂 | 小鵬汽車Q1營收同比下降17.6%，Q2交付和營收預期強勁，預計Robotaxi、人形機器人年內實現量產
財報前瞻 | 股價跌跌不休！美團Q1財報能否驗證拐點逆轉行情？機構料「至暗時刻」已過！
港股異動 | 智譜午后漲勢擴大至9%！總市值逼近7000億港元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
